 | |||||
| lose weight | |||||
| NEWS | |||||
| Semaglutide: weighing up the benefits and risks - The Lancet Diabetes & Endocrinology The landscape of weight loss has changed dramatically. Semaglutide, a GLP-1 receptor analogue, was originally intended to treat diabetes (brand ...
| |||||
| See more results | Edit this alert | |||||
| You have received this email because you have subscribed to Google Alerts. |
 Receive this alert as RSS feed |
| Send Feedback |
